- Home
- BBT vs CLDX Comparison
BBT vs CLDX Comparison
Compare BBT & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBT | CLDX |
|---|---|---|
| Founded | 1846 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | BBT | CLDX |
|---|---|---|
| Price | $28.29 | $26.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $33.00 | ★ $44.10 |
| AVG Volume (30 Days) | 610.5K | ★ 710.6K |
| Earning Date | 01-28-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $318,120,000.00 | $2,599,000.00 |
| Revenue This Year | $66.62 | N/A |
| Revenue Next Year | $68.43 | $23.23 |
| P/E Ratio | $298.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.27 | $14.40 |
| 52 Week High | $30.50 | $30.50 |
Technical Indicators
Market Signals| Indicator | BBT | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 59.40 | 49.94 |
| Support Level | $27.71 | $25.40 |
| Resistance Level | $29.63 | $26.96 |
| Average True Range (ATR) | 0.73 | 1.12 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 57.98 | 42.51 |
Price Performance
Historical ComparisonAbout BBT Beacon Financial Corporation
Beacon Financial Corp operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.